{
    "ticker": "CGTX",
    "name": "Cogent Biosciences, Inc.",
    "description": "Cogent Biosciences, Inc. is a biotechnology company focused on developing transformative therapies for patients with genetically defined diseases. Founded in 2015, Cogent aims to leverage its proprietary drug discovery platform and deep expertise in genetics to create targeted therapies that can address the underlying causes of diseases rather than just their symptoms. The company is particularly known for its innovative approach to precision medicine, which involves tailoring treatments based on individual genetic profiles. Cogent's lead product candidate, CGT9486, is designed to inhibit a specific genetic mutation associated with certain cancers, showcasing the company's commitment to addressing unmet medical needs. In addition to CGT9486, Cogent is expanding its pipeline with several other promising candidates that target a range of disorders, including rare genetic conditions and prevalent diseases. The company's mission is to harness the power of genetic insights to deliver effective, safe, and personalized therapies that improve patient outcomes and quality of life. With a strong foundation in scientific research and a patient-centric approach, Cogent Biosciences is positioned to make a significant impact in the biotechnology landscape.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2015",
    "website": "https://www.cogentbiosciences.com",
    "ceo": "Andrew J. C. K. H. B. K. Y. P. K. P. W. K. C. K. W. M. K. W. K. W. K. W. K. W. K.",
    "social_media": {
        "twitter": "https://twitter.com/CogentBio",
        "linkedin": "https://www.linkedin.com/company/cogent-biosciences/"
    },
    "investor_relations": "https://investors.cogentbiosciences.com",
    "key_executives": [
        {
            "name": "Andrew J. C. K. H. B. K. Y. P. K. P. W. K. C. K. W. M. K. W. K. W. K.",
            "position": "CEO"
        },
        {
            "name": "David G. K. W. K. W. K. W. K.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "CGT9486",
                "Additional Pipeline Candidates"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cogent Biosciences, Inc. | Transforming Genetic Diseases",
        "meta_description": "Explore Cogent Biosciences, Inc., a leader in biotechnology focused on developing innovative therapies for genetically defined diseases. Discover our pipeline and commitment to precision medicine.",
        "keywords": [
            "Cogent Biosciences",
            "Biotechnology",
            "Precision Medicine",
            "Gene Therapy",
            "CGT9486"
        ]
    },
    "faq": [
        {
            "question": "What is Cogent Biosciences known for?",
            "answer": "Cogent Biosciences is known for developing targeted therapies for genetically defined diseases using precision medicine."
        },
        {
            "question": "Who is the CEO of Cogent Biosciences?",
            "answer": "Andrew J. C. K. H. B. K. Y. P. K. P. W. K. C. K. W. M. K. W. K. W. K. is the CEO of Cogent Biosciences, Inc."
        },
        {
            "question": "Where is Cogent Biosciences headquartered?",
            "answer": "Cogent Biosciences is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are Cogent's main products?",
            "answer": "Cogent's main product candidate is CGT9486, along with additional pipeline candidates targeting various genetic diseases."
        },
        {
            "question": "When was Cogent Biosciences founded?",
            "answer": "Cogent Biosciences was founded in 2015."
        }
    ],
    "competitors": [
        "CRIS",
        "EDIT",
        "SGMO",
        "VRTX"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "GILD",
        "BMY"
    ]
}